Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Arthritis & Rheumatism

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 11465699
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of sodium fluoride on the prevention of corticosteroid-induced osteoporosis

  2007cited by this paper
• Testosterone therapy in glucocorticoid-treated men

  2006cited by this paper
• Salmon calcitonin in the therapy of corticoid-induced osteoporosis

  2004cited by this paper
• Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.

  2001cited by this paper
• Use of Inhaled Corticosteroids and Risk of Fractures

  2001cited by this paper
• Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis.

  2000cited by this paper
• Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.

  2000cited by this paper
• Use of oral corticosteroids in the United Kingdom.

  2000cited by this paper
• Bone Mass Continues to Increase at the Hip After Parathyroid Hormone Treatment Is Discontinued in Glucocorticoid‐Induced Osteoporosis: Results of a Randomized Controlled Clinical Trial

  2000cited by this paper
• Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy

  2000cited by this paper
• Corticosteroid Osteoporosis: Practical Implications of Recent Trials

  2000cited by this paper
• Oral corticosteroids and fracture risk: relationship to daily and cumulative doses.

  2000cited by this paper
• A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists.

  2000cited by this paper
• Bisphosphonates for steroid induced osteoporosis.

  2000cited by this paper
• Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

  1999cited by this paper
• Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin.

  1999cited by this paper
• New Developments in the Pathogenesis and Treatment of Steroid‐Induced Osteoporosis

  1999cited by this paper
• Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

  1999cited by this paper
• Prophylactic Use of Alfacalcidol in Corticosteroid-Induced Osteoporosis

  1999cited by this paper
• The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach.

  1999cited by this paper
• Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.

  1998cited by this paper
• Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.

  1998cited by this paper
• Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.

  1998cited by this paper
• Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease.

  1998cited by this paper
• Bone densitometry: clinical considerations.

  1998cited by this paper
• Variations in physicians' judgments about corticosteroid induced osteoporosis by physician specialty.

  1998cited by this paper
• Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis.

  1997cited by this paper
• Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.

  1997cited by this paper
• Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.

  1997cited by this paper
• Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

  1997cited by this paper
• Calcium and Vitamin D3 Supplementation Prevents Bone Loss in the Spine Secondary to Low-Dose Corticosteroids in Patients with Rheumatoid Arthritis

  1996cited by this paper
• A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica

  1996cited by this paper
• Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study

  1996cited by this paper
• Is continuous intranasal salmon calcitonin effective in treating axial bone loss in patients with active rheumatoid arthritis receiving low dose glucocorticoid therapy?

  1996cited by this paper
• Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?

  1996cited by this paper
• Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines.

  1996cited by this paper
• Steroid induced osteoporosis: an opportunity for prevention?

  1995cited by this paper
• Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study.

  1994cited by this paper
• Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events.

  1994cited by this paper
• Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids.

  1994cited by this paper
• Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.

  1993cited by this paper
• Fractures in rheumatoid arthritis: an evaluation of associated risk factors.

  1993cited by this paper
• The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate.

  1991cited by this paper
• Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study.

  1990cited by this paper
• Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate

  1990cited by this paper
• Bone mineral density after resumption of menses in amenorrheic athletes.

  1986cited by this paper
• Bone mineral content of amenorrheic and eumenorrheic athletes.

  1984cited by this paper
• Steroid-induced fractures and bone loss in patients with asthma.

  1983cited by this paper

• The role of dietary factors in the prevention and management of inflammatory bowel disease: a comprehensive review

  2025cites this paper
• Bone structural parameters as measured by 3D-DXA are superior in Black women and demonstrate unique associations with prior fracture versus White women.

  2024cites this paper
• Comparison of bone turnover suppression in atypical femoral fractures and osteoporotic hip fractures

  2024cites this paper
• 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis

  2023cites this paper
• Association between dietary selenium intake and the prevalence of osteoporosis and its role in the treatment of glucocorticoid-induced osteoporosis

  2023cites this paper
• 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis

  2023cites this paper
• Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Aortitis Presenting With Acute Dissection: Case Report and Comprehensive Literature Review.

  2022cites this paper
• Threshold based on bone mineral density for therapeutic decision-making in postmenopausal women and men over 50 years old under glucocorticoid therapy.

  2022cites this paper
• Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover

  2022cites this paper
• The prevalence of osteoporosis/osteopenia in patients with multiple sclerosis (MS): a systematic review and meta-analysis

  2022cites this paper
• The effect of deer antler from East Kalimantan to increase trabecular bone density and calcium levels in serum on osteoporotic mice

  2021cites this paper
• Late Effects of Allogeneic Hematopoietic Stem Cell Transplantation in an Asian Patient Population

  2021cites this paper
• Corticosteroid induced avascular necrosis and COVID-19: The drug dilemma

  2021cites this paper
• Effect of vitamin D therapy on bone mineral density in patients with diabetic nephropathy; a randomized, double-blind placebo controlled clinical trial

  2021cites this paper
• Factors associated with osteoporosis medication use in Japanese patients with rheumatoid arthritis: Results from the Institute of Rheumatology Rheumatoid Arthritis cohort study

  2020cites this paper
• Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study

  2020cites this paper
• Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study

  2020cites this paper
• Intervention Thresholds for Treatment in Patients with Glucocorticoid-Induced Osteoporosis: Systematic Review of Guidelines

  2020cites this paper
• A retrospective database study of oral corticosteroid and bisphosphonate prescribing patterns in England

  2020cites this paper
• Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus.

  2019cites this paper
• DEXAMETHASONE: CHONDROPROTECTIVE CORTICOSTEROID OR CATABOLIC KILLER?

  2019cites this paper
• Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study

  2018cites this paper
• Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment

  2018cites this paper
• Treating Immune-Related Epilepsy

  2018cites this paper
• Ethnic Differences in Trabecular Bone Score.

  2017cites this paper
• Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial.

  2017cites this paper
• 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis

  2017cites this paper
• Les connaissances sur l’ostéoporose cortisonique chez les malades hospitalisés à l’Hôpital Moulay Youssef de Rabat au Maroc

  2017cites this paper
• Promotion effect of extracts from plastrum testudinis on alendronate against glucocorticoid-induced osteoporosis in rat spine

  2017cites this paper
• Contemporary Use of Corticosteroids in Rhinology

  2017cites this paper
• A Prospective Observational Study on Effect of Short‐Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO‐01)

  2017cites this paper
• Prevalence and risk factors associated with glucocorticoid-induced osteoporosis in Chinese patients with rheumatoid arthritis

  2017cites this paper
• Current concepts regarding calcium metabolism and bone health in sarcoidosis

  2017cites this paper
• Muskuloskelettale Manifestationen der Sarkoidose

  2017cites this paper
• Autoimmune Hypothyroidism As a Predictor of Mortality in Chronic Hypersensitivity Pneumonitis

  2017cites this paper
• Late effects of blood and marrow transplantation

  2017cites this paper
• Analysis of bone metabolism during early stage and clinical benefits of early intervention with alendronate in patients with systemic rheumatic diseases treated with high-dose glucocorticoid: Early DIagnosis and Treatment of OsteopoRosis in Japan (EDITOR-J) study

  2016cites this paper
• Case Studies Illustrating Focal Alzheimer's, Fluent Aphasia, Late-Onset Memory Loss, and Rapid Dementia.

  2016cites this paper
• Prevalence of osteoporosis in the Italian population and main risk factors: results of BoneTour Campaign

  2016cites this paper
• Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy–Induced Osteoporosis Treated With Alendronate or Teriparatide

  2016cites this paper
• Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database

  2016cites this paper
• Bone health in patients with multiple sclerosis relapses.

  2016cites this paper
• Skeletal Fragility in Endogenous Hypercortisolism.

  2016cites this paper
• Long-term side effects of glucocorticoids

  2016cites this paper
• Very high frequency of fragility fractures associated with high-dose glucocorticoids in postmenopausal women: A retrospective study

  2016cites this paper
• Changes in Nonosteoporotic Bone Density and Subsequent Fractures in Women

  2016cites this paper
• Risk factors for decreased bone mineral density in inflammatory bowel disease: A cross-sectional study.

  2015cites this paper
• Bone mineral density reduction in adolescents with systemic erythematosus lupus: association with lack of vitamin D supplementation

  2015cites this paper
• [Growth in steroid-responsive nephrotic syndrome in Cote d'Ivoire].

  2015cites this paper
• Curcumin alleviates glucocorticoid-induced osteoporosis through the regulation of the Wnt signaling pathway

  2015cites this paper
• United States Adults Meeting 2010 American College of Rheumatology Criteria for Treatment and Prevention of Glucocorticoid‐Induced Osteoporosis

  2014cites this paper
• Pragmatic approaches to therapy for systemic lupus erythematosus

  2014cites this paper
• The influence of corticosteroid treatment on the OPG/RANK/RANKL pathway and osteocalcin in patients with pemphigus

  2014cites this paper
• Atypical femoral fractures: retrospective radiological study of 319 femoral fractures and presentation of clinical cases

  2014cites this paper
• Bone safety of low‐dose glucocorticoids in rheumatic diseases

  2014cites this paper
• Dexamethasone treatment alters function of adipocytes from a mesenchymal stromal cell line.

  2014cites this paper
• Longitudinal practice patterns of prophylaxis of glucocorticoid-induced osteoporosis in patients with polymyalgia rheumatica

  2014cites this paper
• Rates of Non-vertebral Osteoporotic Fractures in Rheumatoid Arthritis and Postfracture Osteoporosis Care in a Period of Evolving Clinical Practice Guidelines

  2014cites this paper
• Simplified criteria for selecting patients for vertebral fracture assessment.

  2014cites this paper
• Osteoporosis management among chronic glucocorticoid users: a systematic review.

  2014cites this paper
• Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection

  2014cites this paper
• Glucocorticoids in laryngology: A review

  2014cites this paper
• Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study

  2014cites this paper
• Utility of heel dual-energy X-ray absorptiometry in diagnosing osteoporosis.

  2014cites this paper
• Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update

  2014cites this paper
• Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.

  2013cites this paper
• Recent Advances in the Non-invasive Diagnosis of Renal Osteodystrophy

  2013cites this paper
• Non-adherence to anti-osteoporotic medications in Taiwan: physician specialty makes a difference

  2013cites this paper
• Recent recommendations on steroid-induced osteoporosis: More targeted, but more complicated

  2013cites this paper
• Inflammatory bowel disease and exercise: results of a Crohn's and Colitis UK survey

  2013cites this paper
• Treatment of sarcoidosis.

  2013cites this paper
• Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.

  2013cites this paper
• Glucocorticoid therapy as a significant risk factor for osteoporosis and fractures in an Italian postmenopausal population

  2013cites this paper
• Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy

  2013cites this paper
• Inflammatory bowel disease and the risk of osteoporosis and fracture.

  2013cites this paper
• Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis

  2013cites this paper
• Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.

  2013cites this paper
• The role of vitamin D supplementation in patients with rheumatic diseases

  2013cites this paper
• Prevalence of oral glucocorticoid usage in the United States: A general population perspective

  2013cites this paper
• Review of New Guidelines for the Management of Glucocorticoid Induced Osteoporosis

  2013cites this paper
• Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review

  2013cites this paper
• Bone mineral density in asthmatic patients on inhaled corticosteroids in a developing country

  2012cites this paper
• Corticosteroid-Induced Osteoporosis

  2012cites this paper
• Do the hospitalized patients with osteoporotic fractures require endocrinologists’ help?

  2012cites this paper
• Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation

  2012cites this paper
• Guidelines for the Use of Corticosteroids in the Treatment of Pulmonary Sarcoidosis

  2012cites this paper
• An appendix to the 2012 IOF–ECTS guidelines for the management of glucocorticoid-induced osteoporosis

  2012cites this paper
• Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis

  2012cites this paper
• Bone loss and avascular necrosis of bone after hematopoietic cell transplantation.

  2012cites this paper
• Corticosteroid use in autoimmune blistering diseases.

  2012cites this paper
• Development of macromolecular prodrug for rheumatoid arthritis.

  2012cites this paper
• Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort.

  2012cites this paper
• A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

  2012cites this paper
• Potential benefits of vitamin D for patients with systemic lupus erythematosus

  2012cites this paper
• Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.

  2012cites this paper
• Treatment for older men with fractures

  2012cites this paper
• Clinical role of bisphosphonate therapy

  2012cites this paper
• Adherence to anti‐osteoporotic regimens in a Southern Taiwanese population treated according to guidelines: a hospital‐based study

  2012cites this paper
• Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation

  2012cites this paper
• Factors associated with treatment of women with osteoporosis or osteopenia from a national survey

  2012cites this paper